If Linzess isn’t giving you relief, you’re in a surprisingly large group. In clinical trials for IBS-C, only about 34% of patients met the strict responder criteria, meaning roughly two out of three people didn’t hit the primary benchmark for success. That doesn’t necessarily mean the medication has failed you, though. Before moving on, there are several factors worth checking and a clear set of next steps if it truly isn’t the right fit.
Give It Enough Time
Linzess can start increasing bowel movements within the first week, but the full effect takes longer. In clinical trials, maximum improvements in abdominal pain took 6 to 8 weeks to develop and then held steady from there. If you’ve only been on it for two or three weeks, the medication may not have reached its peak yet. Judging it too early is one of the most common reasons people switch away from something that might have worked.
Check How You’re Taking It
Timing matters more with Linzess than with most medications. It should be taken on an empty stomach, ideally one to two hours before your first meal of the day. Taking it with food or shortly before eating can significantly reduce how well it works. Take it at roughly the same time each day, and if you miss a dose, skip it rather than doubling up the next day.
These sound like small details, but inconsistent timing is one of the easiest problems to fix and one of the most overlooked reasons the drug underperforms.
Make Sure You’re on the Right Dose
Linzess comes in three strengths: 72, 145, and 290 micrograms. The recommended dose depends on your condition. For IBS-C in adults, the FDA-approved dose is 290 mcg. For chronic idiopathic constipation, it’s 145 mcg, with 72 mcg available for people who need a lower dose based on tolerability. If you were started on a lower dose for comfort, there may be room to increase it. Conversely, if you were prescribed 145 mcg for CIC and it’s not enough, your doctor may consider whether your symptoms better fit an IBS-C diagnosis warranting the higher dose.
A Pelvic Floor Problem Can Make Any Laxative Fail
Linzess works by drawing fluid into the intestines and speeding up movement through the gut. But if the problem isn’t slow movement, it’s that your muscles aren’t coordinating properly when you try to go, no amount of extra fluid will solve it. This condition, called dyssynergic defecation or pelvic floor dysfunction, affects a meaningful number of people diagnosed with chronic constipation.
The hallmark signs include excessive straining, a persistent feeling of incomplete evacuation, and sometimes needing to use manual pressure to help stool pass. In one study, 85% of patients with this disorder reported excessive straining and 75% reported feeling like they couldn’t fully empty. People with pelvic floor dysfunction also tend to respond poorly to fiber supplements, which is another clue.
A doctor can screen for this with a careful physical exam, checking whether the pelvic floor muscles relax properly when you bear down. More definitive testing involves anorectal manometry (a pressure test) and a balloon expulsion test, where you attempt to pass a small water-filled balloon within one to two minutes. If you can’t, that points toward a coordination problem rather than a motility problem. The treatment for dyssynergic defecation is biofeedback therapy, which retrains the muscles, not more medication.
Prescription Alternatives Worth Discussing
If Linzess genuinely isn’t working after adequate time at the right dose, several other prescription options target constipation through different pathways.
Trulance (plecanatide) works through the same general mechanism as Linzess, activating receptors on the intestinal lining that increase fluid secretion. It’s closely related but not identical, and some people respond to one but not the other. Current clinical guidelines give it the same strong recommendation as Linzess for chronic constipation.
Amitiza (lubiprostone) takes a different approach, activating chloride channels in the gut to pull fluid into the intestines. In indirect comparison analyses, it ranked just behind Linzess in likelihood of achieving a bowel movement response over four weeks. It carries a conditional rather than strong recommendation in guidelines, reflecting slightly weaker evidence, but it remains a reasonable option.
Motegrity (prucalopride) works through an entirely different mechanism. Instead of increasing fluid, it stimulates serotonin receptors in the gut wall to strengthen the muscular contractions that push stool forward. This makes it a particularly logical next step if your constipation seems driven more by slow transit than by hard, dry stools. Guidelines give it a strong recommendation alongside Linzess and Trulance.
Ibsrela (tenapanor) is specifically approved for IBS-C and works by blocking sodium absorption in the small intestine, which increases fluid in the stool. In a 26-week trial, about 37% of patients met the combined responder endpoint compared to 24% on placebo, with nearly half reporting meaningful improvement in abdominal pain. It was developed specifically because many patients with IBS-C don’t get adequate relief from existing options.
Adding Over-the-Counter Options
You don’t necessarily have to abandon Linzess entirely. Clinical guidelines note that prescription agents can be used as an adjunct to over-the-counter therapies, not just as replacements. Osmotic laxatives like polyethylene glycol (MiraLAX) have only a minor interaction with Linzess and no therapeutic duplication warning, meaning combining them is generally feasible. That said, adding a second agent that draws water into the gut increases the chance of diarrhea, so this is a conversation to have with your prescriber rather than something to experiment with on your own.
Ruling Out Slow Transit Constipation
If multiple medications have failed, your doctor may want to investigate whether stool is physically moving too slowly through your colon. A whole-gut transit study, often done by swallowing a capsule containing tiny markers and then taking an X-ray several days later to see where they are, can measure how quickly material moves through different segments of the colon. Slow transit constipation is a distinct motility disorder where the colon’s contractions are genuinely sluggish. Identifying it changes the treatment approach and, in severe refractory cases, can eventually point toward surgical options.
The key distinction matters: slow transit constipation, pelvic floor dysfunction, and IBS-C can all feel similar from the outside but respond to very different treatments. Getting the right diagnosis is often more productive than cycling through another medication.